ArticleLeukemia2017
Rare germline variants in ATM are associated with chronic lymphocytic leukemia.
Open access · greenAbstract read
In one paragraph
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Pooled it
- ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.Leukemia · 2025Article
- Rare germline ATM variants predispose to secondary cancer in chronic lymphocytic leukaemia patients.Cancer communications (London, England) · 2025Article
- Investigating the influence of germlineHaematologica · 2025Article
- Germline Variant Spectrum in Southern Italian High-Risk Hereditary Breast Cancer Patients: Insights from Multi-Gene Panel Testing.Current issues in molecular biology · 2024Article
- Clinical Risks for Chronic Lymphocytic Leukemia.Journal of the National Comprehensive Cancer Network : JNCCN · 2024Review
- Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome.International journal of molecular sciences · 2024Review
- Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.Pharmaceutics · 2023Review
- Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms.Leukemia · 2023Article
- Rare GermlineJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma.International journal of molecular sciences · 2022Article
- Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.Current hematologic malignancy reports · 2022Review
- Article
- Article
- Article
- Exome-Wide Pan-Cancer Analysis of Germline Variants in 8,719 Individuals Finds Little Evidence of Rare Variant Associations.Human heredity · 2021Article
- Article
- Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.Cancer genetics · 2019Article
- Article
- Analysis ofBlood · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 2 countries.
G TiaoCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
M R ImprogoCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
S KasarCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
W PohCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
A KamburovCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
D-A LandauCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
E TauschDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
A Taylor-WeinerCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
C CibulskisCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
S BahlCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
S M FernandesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
K HoangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
E RheinbayCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
H T KimDepartment of Computational Biology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA.
J BahloDepartment I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
S RobrechtDepartment I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
K FischerDepartment I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
M HallekDepartment I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany.
S GabrielCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
E S LanderCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
S StilgenbauerDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
C J WuCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
A KiezunCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
G GetzCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
J R BrownCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Broad Institute · USHarvard University · USUniversity Hospital Cologne · DEBrigham and Women's Hospital · USUniversität Ulm · DEDana-Farber Cancer Institute · US
Funding
ProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI LETAI, ANTHONY G · 2016 to 2025
$17.0M(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemiaR01CA216273 · NCI · DANA-FARBER CANCER INST · PI WANG, LILI, WU, CATHERINE JU-YING · 2017 to 2021
$3.5MITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4M(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLLR01CA184922 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2014 to 2017
$2.2MDefining the impact of clonal evolution on chronic lymphocytic leukemiaR01CA182461 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2014 to 2018
$1.8MGenetic Alterations in Families with Multiple LymphomasK23CA115682 · NCI · DANA-FARBER CANCER INSTITUTE · PI BROWN, JENNIFER R · 2005 to 2009
$754kNCI NIH HHS K23 CA115682NCI NIH HHS P01 CA206978NCI NIH HHS R01 CA182461NCI NIH HHS R01 CA184922NCI NIH HHS R01 CA216273NCI NIH HHS U10 CA180861
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAtaxia Telangiectasia Mutated ProteinsCase-Control StudiesFemaleGene FrequencyGenetic Predisposition to DiseaseGerm-Line MutationHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedAtaxia Telangiectasia Mutated ProteinsATM protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.